KZIA - Kazia Therapeutics Ltd ADR

https://www.kaziatherapeutics.com

Recent News

Kazia Therapeutics Announces $2 Million Private Placement at Premium to Market - Kazia Therapeutics ( NASDAQ:KZIA )

Benzinga • 1 month, 2 weeks ago • score: 0.27

SYDNEY, Aug. 1, 2025 /PRNewswire/ -- Kazia Therapeutics Limited KZIA, an oncology-focused drug development company, today announced that it has entered into a securities purchase agreement with certain established institutional investors for a private placement of equity securities ( PIPE ) .

Bullish

Kazia Therapeutics ( KZIA ) Stock Surges 77% On Positive Preclinical Data For Breast Cancer Drug - Kazia Therapeutics ( NASDAQ:KZIA )

Benzinga • 3 months ago • score: 0.28

Kazia on Wednesday announced positive preclinical data for its paxalisib drug in triple-negative breast cancer. The company's stock is soaring over 77% on exceptionally high and unusual trading volume. Get the Strategy to Trade Pre-Fed Setups and Post-Fed Swings-Live With Chris Capre on ...

Interval:

EMA1: EMA2:

AI Tools

Key Metrics

Trend: Downtrend

Source: Snapshot

Kazia Therapeutics Limited, a biotechnology company focused on oncology, develops anticancer drugs. The company is headquartered in Sydney, Australia.

52W High

$39.05

52W Low

$2.86

MA Status:

50D: Below 200D: Below

Beta (~1 neutral, <0.9 lower risk)

2.20

Valuation

As of 2024-09-30 (Overview)

Trailing P/E (<15 better)

N/A

Forward P/E (<15 better)

N/A

EV/EBITDA (<8 favorable)

-0.71

EV/Revenue (<3 favorable)

4.50

P/S (TTM) (<3 favorable)

4.22

P/B (<3 favorable)

3.09

Ownership

Retail‑heavy

Source: Overview

Insiders (1–5% typical)

8.48%

Institutions (25–75% balanced)

8.91%

Shares Outstanding

1,359,600

Float

422,581,000

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

Profitability: Weak

As of 2024-09-30 (Overview)

Revenue (TTM)

2,503,300

Gross Profit (TTM)

2,503,300

EPS (TTM)

-29.25

Profit Margin (>10% good)

N/A

Operating Margin (TTM) (higher better)

-420.30%

ROE (TTM) (>15% strong)

-38.92%

EPS YoY (Quarterly) (>10% good)

N/A

Revenue YoY (Quarterly) (>8% good)

5571.50

Momentum

Value

N/A

Trend

—

Signal Cross

No cross

As of

—